Compare Ascendis Pharma A/S (ASND) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Endeavour Silver Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Endeavour Silver Corp trades at $7.85 (market cap $2.39B). The key difference: Ascendis Pharma A/S is far larger — about 7.4× Endeavour Silver Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| ASND | EXK | |
|---|---|---|
Market Cap | $17.74B | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $14.12 |
52-Week Low | $163.32 | $4.96 |
Enterprise Value | $18.11B | $2.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Endeavour Silver (EXK) trades at $8.08, down 1.94% with bearish technical signals despite strong Q2 2026 production results. The company shows improving fundamentals with Q1 2026 earnings beating estimates at $0.21 per share versus $0.10 expected, while revenue trends project growth from $468M in 2025 to $614M in 2026. Analyst sentiment remains overwhelmingly positive with 11 buy ratings out of 14 total recommendations.
EXK presents a recovery opportunity as silver prices strengthen and production expands, though negative net margins and high valuation ratios pose near-term risks. The expiration of silver collars in June 2026 could unlock significant cash flow, providing catalysts for upside potential despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
